Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
37
CLPT Quote, Financials, Valuation and Earnings
Last price:
$14.51
Seasonality move
:
17.82%
Day range:
$14.01 - $14.57
52-week range:
$9.76 - $30.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.72x
P/B ratio:
25.73x
Volume:
397.7K
Avg. volume:
698.5K
1-year change:
-1.78%
Market cap:
$408.4M
Revenue:
$31.4M
EPS (TTM):
-$0.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLPT
Clearpoint Neuro, Inc.
|
$9.6M | -$0.20 | 29.33% | -2.56% | $29.00 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
IART
Integra LifeSciences Holdings Corp.
|
$414.3M | $0.43 | -2.94% | 217.65% | $15.50 |
|
MASI
Masimo Corp.
|
$366.9M | $1.20 | -32.15% | 565.51% | $183.75 |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLPT
Clearpoint Neuro, Inc.
|
$14.37 | $29.00 | $408.4M | -- | $0.00 | 0% | 11.72x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7250 | $12.3077 | $202.6M | -- | $0.00 | 0% | 184.77x |
|
IART
Integra LifeSciences Holdings Corp.
|
$12.59 | $15.50 | $980.7M | 70.14x | $0.00 | 0% | 0.59x |
|
MASI
Masimo Corp.
|
$133.87 | $183.75 | $7.2B | 116.80x | $0.00 | 0% | 4.23x |
|
VNRX
VolitionRX Ltd.
|
$0.25 | $2.20 | $31.3M | -- | $0.00 | 0% | 17.45x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $109.2M | 76.47x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLPT
Clearpoint Neuro, Inc.
|
69.25% | 2.170 | 5.77% | 5.56x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
IART
Integra LifeSciences Holdings Corp.
|
65.91% | 0.130 | 179.84% | 1.47x |
|
MASI
Masimo Corp.
|
41.99% | 0.805 | 7.4% | 1.68x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLPT
Clearpoint Neuro, Inc.
|
$5.6M | -$5.3M | -60.29% | -105.19% | -59.54% | -$3.3M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
IART
Integra LifeSciences Holdings Corp.
|
$226.1M | $25.9M | -14.85% | -37.15% | 6.43% | $25.8M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Clearpoint Neuro, Inc. vs. Competitors
-
Which has Higher Returns CLPT or CATX?
Perspective Therapeutics, Inc. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of -12425.36%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital CLPTClearpoint Neuro, Inc.63.2% -$0.21 $51.6M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About CLPT or CATX?
Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 101.81%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 331.85%. Given that Perspective Therapeutics, Inc. has higher upside potential than Clearpoint Neuro, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Clearpoint Neuro, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLPTClearpoint Neuro, Inc.2 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is CLPT or CATX More Risky?
Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock CLPT or CATX?
Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLPT or CATX?
Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Clearpoint Neuro, Inc.'s net income of -$5.9M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.72x versus 184.77x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLPTClearpoint Neuro, Inc.11.72x -- $8.9M -$5.9M CATXPerspective Therapeutics, Inc.184.77x -- $209K -$26M
-
Which has Higher Returns CLPT or IART?
Integra LifeSciences Holdings Corp. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of -1.34%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.
Company Gross Margin Earnings Per Share Invested Capital CLPTClearpoint Neuro, Inc.63.2% -$0.21 $51.6M IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B -
What do Analysts Say About CLPT or IART?
Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 101.81%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 23.11%. Given that Clearpoint Neuro, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Clearpoint Neuro, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings CLPTClearpoint Neuro, Inc.2 0 0 IARTIntegra LifeSciences Holdings Corp.2 4 2 -
Is CLPT or IART More Risky?
Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.408%.
-
Which is a Better Dividend Stock CLPT or IART?
Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLPT or IART?
Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.72x versus 0.59x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLPTClearpoint Neuro, Inc.11.72x -- $8.9M -$5.9M IARTIntegra LifeSciences Holdings Corp.0.59x 70.14x $402.1M -$5.4M
-
Which has Higher Returns CLPT or MASI?
Masimo Corp. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of 14.46%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital CLPTClearpoint Neuro, Inc.63.2% -$0.21 $51.6M MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About CLPT or MASI?
Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 101.81%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 37.26%. Given that Clearpoint Neuro, Inc. has higher upside potential than Masimo Corp., analysts believe Clearpoint Neuro, Inc. is more attractive than Masimo Corp..
Company Buy Ratings Hold Ratings Sell Ratings CLPTClearpoint Neuro, Inc.2 0 0 MASIMasimo Corp.4 3 0 -
Is CLPT or MASI More Risky?
Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.
-
Which is a Better Dividend Stock CLPT or MASI?
Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLPT or MASI?
Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Masimo Corp.'s net income of $53.7M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.72x versus 4.23x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLPTClearpoint Neuro, Inc.11.72x -- $8.9M -$5.9M MASIMasimo Corp.4.23x 116.80x $371.5M $53.7M
-
Which has Higher Returns CLPT or VNRX?
VolitionRX Ltd. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of -862.39%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLPTClearpoint Neuro, Inc.63.2% -$0.21 $51.6M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About CLPT or VNRX?
Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 101.81%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 763.76%. Given that VolitionRX Ltd. has higher upside potential than Clearpoint Neuro, Inc., analysts believe VolitionRX Ltd. is more attractive than Clearpoint Neuro, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLPTClearpoint Neuro, Inc.2 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is CLPT or VNRX More Risky?
Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock CLPT or VNRX?
Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLPT or VNRX?
Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.72x versus 17.45x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLPTClearpoint Neuro, Inc.11.72x -- $8.9M -$5.9M VNRXVolitionRX Ltd.17.45x -- $627.3K -$5.4M
-
Which has Higher Returns CLPT or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of 3.93%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital CLPTClearpoint Neuro, Inc.63.2% -$0.21 $51.6M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About CLPT or XTNT?
Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 101.81%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.31%. Given that Clearpoint Neuro, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Clearpoint Neuro, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLPTClearpoint Neuro, Inc.2 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is CLPT or XTNT More Risky?
Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock CLPT or XTNT?
Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLPT or XTNT?
Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.72x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLPTClearpoint Neuro, Inc.11.72x -- $8.9M -$5.9M XTNTXtant Medical Holdings, Inc.0.85x 76.47x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
